Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-SIRP monoclonal antibody ELA026

A human immunoglobulin G1 (IgG1) monoclonal antibody targeting certain specific proteins of the human signal-regulatory protein (SIRP) family, with potential immunoregulatory activity. Upon administration, anti-SIRP monoclonal antibody ELA026 targets and binds to SIRP, a cell surface protein expressed on myeloids and T lymphocytes. This depletes pathological myeloids and T lymphocytes that are circulating due to excessive immune activation and inflammation. This eradicates pathological immune cells that are driving inflammation. SIRP is a family of cell surface receptors expressed on various immune cell types. ELA026 does not inhibit the activity of the SIRPalpha/CD47 immune checkpoint.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:SIRP-directed monoclonal antibody ELA026
Code name:ELA 026
ELA-026
ELA026
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search